Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
8.88
-0.88 (-9.02%)
Jan 26, 2026, 4:00 PM EST - Market closed
Kyverna Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
129
Market Cap
507.31M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 7.03M | 1.37M | 24.20% |
| Dec 31, 2021 | 5.66M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKYTX News
- 15 days ago - Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference - GlobeNewsWire
- 22 days ago - Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies - Seeking Alpha
- 5 weeks ago - Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript - Seeking Alpha
- 5 weeks ago - Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock - GlobeNewsWire
- 5 weeks ago - Kyverna Therapeutics: "Strong Buy" Rating As Positive SPS Data Leads To 1st Half 2026 BLA Filing - Seeking Alpha
- 6 weeks ago - Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 6 weeks ago - Kyverna Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire